RxDoctor Payments Data

Matthew Luedke, MD

Clinical Neurophysiology · Durham, NCNPI 1144541541

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $5,605 of the $7,162 with a category attached, or 78.3%. 7 manufacturers reported payments, led by Eisai Inc. at 51.3% of the total. 2025 is the largest year on record at $2,876, 3.1 times the $928 reported in 2019.

$7,162in general payments, 2019–2025

Across 22 payments — averaging $325.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eisai Inc.$4K
  • Aucta Pharmaceuticals, Inc.$3K
  • UCB, Inc.$456
  • Neurelis, Inc.$296
  • Jazz Pharmaceuticals Inc.$111
  • SK Life Science, Inc.$101
  • plus $28 from 1 others

What the payments were for

  • Consulting fees$5,60578%
  • Food & beverage$1,55722%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eisai Inc.10$3,671
Aucta Pharmaceuticals, Inc.1$2,500
UCB, Inc.4$456
Neurelis, Inc.3$296
Jazz Pharmaceuticals Inc.1$111
SK Life Science, Inc.1$101
Aquestive Therapeutics, Inc.2$28

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few clinical neurophysiology providers in North Carolinato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$49,470
Medicare patients
304
Services billed
585

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XcopriCenobamate80$129,231
EpidiolexCannabidiol (Cbd)19$100,502
BriviactBrivaracetam51$99,984
FycompaPerampanel52$61,316
Lacosamide218$46,309
NayzilamMidazolam36$40,720
Lamictal XrLamotrigine17$37,714
KeppraLevetiracetam25$34,269
OnfiClobazam17$33,405
Lamotrigine ErLamotrigine63$29,366
LamictalLamotrigine17$26,939
ValtocoDiazepam12$25,147
LyricaPregabalin24$22,432
Keppra XrLevetiracetam11$21,605
VimpatLacosamide12$15,115

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Briviact, Nayzilam, Vimpat$456$155,81899 claims
SK Life Science, Inc.Xcopri$101$129,23180 claims
Eisai Inc.Fycompa$3,671$61,31652 claims
Neurelis, Inc.Valtoco$296$25,14712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical neurophysiology providers in North Carolinaon file to place this against a meaningful peer group, so we don't.

Other clinical neurophysiology in Durham

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →